Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhaled corticosteroids and Stenotrophomonas maltophilia in outpatients with chronic obstructive pulmonary disease: a retrospective cohort study.
Rønn C, Kamstrup P, Heerfordt CK, Sivapalan P, Eklöf J, Boel JB, Ostergaard C, Dessau RB, Moberg M, Janner J, Ulrik CS, Jensen JS. Rønn C, et al. Among authors: janner j. BMJ Open Respir Res. 2024 Mar 9;11(1):e001929. doi: 10.1136/bmjresp-2023-001929. BMJ Open Respir Res. 2024. PMID: 38460975 Free PMC article.
Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients.
Eklöf J, Sørensen R, Ingebrigtsen TS, Sivapalan P, Achir I, Boel JB, Bangsborg J, Ostergaard C, Dessau RB, Jensen US, Browatzki A, Lapperre TS, Janner J, Weinreich UM, Armbruster K, Wilcke T, Seersholm N, Jensen JUS. Eklöf J, et al. Among authors: janner j. Clin Microbiol Infect. 2020 Feb;26(2):227-234. doi: 10.1016/j.cmi.2019.06.011. Epub 2019 Jun 22. Clin Microbiol Infect. 2020. PMID: 31238116 Free article.
Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial.
Sivapalan P, Jørgensen NR, Mathioudakis AG, Eklöf J, Lapperre T, Ulrik CS, Andreassen HF, Armbruster K, Sivapalan P, Janner J, Godtfredsen N, Weinreich UM, Nielsen TL, Seersholm N, Wilcke T, Schuetz P, Klausen TW, Marså K, Vestbo J, Jensen JU. Sivapalan P, et al. Among authors: janner j. Respir Res. 2020 Oct 12;21(1):263. doi: 10.1186/s12931-020-01531-9. Respir Res. 2020. PMID: 33046053 Free PMC article. Clinical Trial.
Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.
Sivapalan P, Rutishauser J, Ulrik CS, Leuppi JD, Pedersen L, Mueller B, Eklöf J, Biering-Sørensen T, Gottlieb V, Armbruster K, Janner J, Moberg M, Lapperre TS, Nielsen TL, Browatzki A, Mathioudakis A, Vestbo J, Schüetz P, Jensen JU. Sivapalan P, et al. Among authors: janner j. Respir Res. 2021 May 21;22(1):155. doi: 10.1186/s12931-021-01745-5. Respir Res. 2021. PMID: 34020641 Free PMC article.
A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.
Sivapalan P, Moberg M, Eklöf J, Janner J, Vestbo J, Laub RR, Browatzki A, Armbruster K, Wilcke JT, Seersholm N, Weinreich UM, Titlestad IL, Andreassen HF, Ulrik CS, Bødtger U, Nielsen TL, Hansen EF, Jensen JUS. Sivapalan P, et al. Among authors: janner j. BMC Pulm Med. 2017 Aug 15;17(1):114. doi: 10.1186/s12890-017-0458-7. BMC Pulm Med. 2017. PMID: 28810909 Free PMC article. Clinical Trial.
Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.
Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, Eklöf J, Holm FS, Armbruster K, Sivapalan P, Mosbech C, Ali AKM, Seersholm N, Wilcke JT, Brøndum E, Sonne TP, Rønholt F, Andreassen HF, Ulrik CS, Vestbo J, Jensen JS. Sivapalan P, et al. Among authors: janner j. Lancet Respir Med. 2019 Aug;7(8):699-709. doi: 10.1016/S2213-2600(19)30176-6. Epub 2019 May 20. Lancet Respir Med. 2019. PMID: 31122894 Clinical Trial.
TOB-STOP-COP (TOBacco STOP in COPd trial): study protocol-a randomized open-label, superiority, multicenter, two-arm intervention study of the effect of "high-intensity" vs. "low-intensity" smoking cessation intervention in active smokers with chronic obstructive pulmonary disease.
Saeed MI, Sivapalan P, Eklöf J, Ulrik CS, Pisinger C, Lapperre T, Tønnesen P, Hoyer N, Janner J, Karlsson ML, Bech CS, Marså K, Godtfredsen N, Brøndum E, Munk B, Raaschou M, Browatzski A, Lütken P, Jensen JS. Saeed MI, et al. Among authors: janner j. Trials. 2020 Aug 21;21(1):730. doi: 10.1186/s13063-020-04653-z. Trials. 2020. PMID: 32825845 Free PMC article.
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease.
Eklöf J, Misiakou MA, Sivapalan P, Armbruster K, Browatzki A, Nielsen TL, Lapperre TS, Andreassen HF, Janner J, Ulrik CS, Gabrielaite M, Johansen HK, Jensen A, Nielsen TV, Hertz FB, Ghathian K, Calum H, Wilcke T, Seersholm N, Jensen JS, Marvig RL. Eklöf J, et al. Among authors: janner j. Clin Microbiol Infect. 2022 Jul;28(7):990-995. doi: 10.1016/j.cmi.2022.01.017. Epub 2022 Feb 3. Clin Microbiol Infect. 2022. PMID: 35124256 Free article. Clinical Trial.
Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population.
Kamstrup P, Sand JMB, Ulrik CS, Janner J, Rønn CP, Rønnow SR, Leeming DJ, Jensen SG, Wilcke T, Mathioudakis AG, Miravitlles M, Lapperre T, Bendstrup E, Frikke-Schmidt R, Murray DD, Itenov T, Bossios A, Nielsen SD, Vestbo J, Biering-Sørensen T, Karsdal M, Jensen JU, Sivapalan P. Kamstrup P, et al. Among authors: janner j. Biomedicines. 2022 Aug 19;10(8):2011. doi: 10.3390/biomedicines10082011. Biomedicines. 2022. PMID: 36009558 Free PMC article.
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial.
Eklöf J, Alispahic IA, Sivapalan P, Wilcke T, Seersholm N, Armbruster K, Kjærgaard JL, Saeed MI, Nielsen TL, Browatzki A, Overgaard RH, Fenlev CS, Harboe ZB, Andreassen HF, Lapperre TS, Pedersen L, Johnsen S, Ulrik CS, Janner J, Moberg M, Heidemann M, Weinreich UM, Vijdea R, Linde H, Titlestad I, Johansson SL, Rosenvinge FS, Østergaard C, Ghathian KSA, Gundersen L, Christensen CW, Bangsborg J, Jensen TT, Sørensen VM, Ellingsgaard T, Datcu R, Coia JE, Bodtger U, Jensen JUS. Eklöf J, et al. Among authors: janner j. Trials. 2022 Sep 27;23(1):817. doi: 10.1186/s13063-022-06720-z. Trials. 2022. PMID: 36167555 Free PMC article. Clinical Trial.
35 results